177 related articles for article (PubMed ID: 29163831)
1. MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis.
Huang X; Sun Q; Chen C; Zhang Y; Kang X; Zhang JY; Ma DW; Xia L; Xu L; Xu XY; Ren BH
Oncotarget; 2017 Oct; 8(52):90315-90326. PubMed ID: 29163831
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis.
Zhu L; Ma G; Liu J; Deng Y; Wu Q; Chen W; Zhou Q
Medicine (Baltimore); 2019 Apr; 98(16):e15069. PubMed ID: 31008931
[TBL] [Abstract][Full Text] [Related]
4. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
7. Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis.
Lu Y; Sun C; Jiao L; Liu Y; Gong Y; Xu L
Front Pharmacol; 2021; 12():698371. PubMed ID: 34512332
[No Abstract] [Full Text] [Related]
8. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis.
Zhang B; Xie Z; Li B
Gene; 2019 Mar; 689():76-83. PubMed ID: 30552981
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.
Zhong A; Xing Y; Pan X; Shi M; Xu H
Onco Targets Ther; 2015; 8():3595-601. PubMed ID: 26664143
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic significance of MUC4 expression in cancers: evidence from meta-analysis.
Huang X; Wang X; Lu SM; Chen C; Wang J; Zheng YY; Ren BH; Xu L
Int J Clin Exp Med; 2015; 8(7):10274-83. PubMed ID: 26379819
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Mucin Antigen MUC1 in Various Human Epithelial Cancers: A Meta-Analysis.
Xu F; Liu F; Zhao H; An G; Feng G
Medicine (Baltimore); 2015 Dec; 94(50):e2286. PubMed ID: 26683959
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis.
Li M; Ma G; Li X; Zhou Q
Med Sci Monit; 2022 Jul; 28():e936898. PubMed ID: 35891604
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang TT; Wang RM; Yang Z; Chen GB
Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis.
Tan Z; Shen W
Oncotarget; 2017 Apr; 8(16):27137-27144. PubMed ID: 28404927
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.
Luo Z; Wu RR; Lv L; Li P; Zhang LY; Hao QL; Li W
Int J Clin Exp Pathol; 2014; 7(7):3632-46. PubMed ID: 25120740
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the impact of de novo and acquired
Liu Y; Sun L; Xiong ZC; Sun X; Zhang SL; Ma JT; Han CB
Onco Targets Ther; 2017; 10():2267-2279. PubMed ID: 28479857
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis.
Hu Y; Shen J; Liu R; Feng Z; Zhang C; Ling L; Chen L
Int J Biol Markers; 2018 Nov; 33(4):372-378. PubMed ID: 30282502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
